| Not Yet Recruiting | Effect of Fufang Biejiaruangan Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in NCT07481032 | Nanfang Hospital, Southern Medical University | N/A |
| Not Yet Recruiting | Entecavir Resistance-Associated Mutations in Chronic HBV Patients in Turkey (STREAM Study) NCT07459426 | Yaşar Bayındır, MD | — |
| Recruiting | Phase 2 Study of AHB-137 in HBeAg Negative Chronic Hepatitis B (CHB) Participants in Asia Pacific Region NCT07370207 | AusperBio Therapeutics Inc. | Phase 2 |
| Recruiting | Oral-Periodontal Evaluation and Assessment of Oral Fluid Biomarkers in Patients With Hepatitis B+D NCT07491848 | Research Center of Periodontal-Systemic Interactions | — |
| Not Yet Recruiting | Use of Gender, Age, Alfa-fetoprotein (AFP), and Des-gamma-carboxyprothrombin (PIVKA-II) or GAAD Score in Addit NCT07298577 | Siriraj Hospital | N/A |
| Not Yet Recruiting | Comparison of a Handheld Elastography Device With iLivTouch in Chronic Liver Disease Patients NCT07242404 | Hong You | — |
| Not Yet Recruiting | Sequential PEG-IFN for HBV After Ending RNA-targeted Regimens NCT06923280 | Huashan Hospital | N/A |
| Recruiting | Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients With Chronic Hepatitis NCT06680232 | Precision BioSciences, Inc. | Phase 1 |
| Recruiting | Improved Sensitivity Detection of Serum HBsAg and HBsAg Reversion NCT06550622 | Huashan Hospital | — |
| Active Not Recruiting | Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB). NCT06550128 | Ausper Biopharma Co., Ltd. | Phase 2 |
| Not Yet Recruiting | A Clinical Study to Evaluate the Efficacy of TQA3038 Injection in Patients With Chronic Hepatitis B NCT06452693 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 / Phase 2 |
| Withdrawn | Study of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab in Subjects With Chronic HBV NCT06245291 | Arbutus Biopharma Corporation | Phase 2 |
| Recruiting | Vaccinal Effect of HBsAg Monoclonal Ab VIR-3434 in Chronic Hepatitis B Infection [VISION] NCT06216470 | University Health Network, Toronto | Phase 2 |
| Recruiting | A Real-world Study of Staging and Grading of Clinical Immune Status in Chronic Hepatitis B NCT06525909 | Tongji Hospital | — |
| Unknown | Development and Validation of Models to Predict Functional Cure in Patients With CHB After Peg-IFN Based Thera NCT06196632 | Qilu Hospital of Shandong University | — |
| Unknown | Individual Nutrition Support in HBV-ACLF Patients at Nutrition Risk NCT06128421 | Third Affiliated Hospital, Sun Yat-Sen University | N/A |
| Unknown | A Non-invasive Model to Predict Antiviral Therapy in Gray Zone of Chronic Hepatitis B NCT06041022 | Qilu Hospital of Shandong University | — |
| Completed | Efficacy and Safety of Switching to Vemliver From Entecavir in Chronic Hepatitis B Patients Previously Treated NCT06000657 | Daewoong Pharmaceutical Co. LTD. | Phase 4 |
| Active Not Recruiting | A Study to Evaluate the Safety and Efficacy of AHB-137 in Healthy Participants and HBeAg-negative Chronic Hepa NCT06115993 | Ausper Biopharma Co., Ltd. | Phase 1 / Phase 2 |
| Unknown | Study IL- 35 Level and Fibronectin Type Ⅲ Domain Containing Protein 5 \ Irsin (FNDC5 rs3480) Gene Variations i NCT06023745 | Sohag University | — |
| Recruiting | Efficacy of NA Combined With PEG-IFN-α2b in the Continuous Versus Pulsed Treatment of Patients With Chronic He NCT05922306 | Anhui Medical University | EARLY_Phase 1 |
| Recruiting | HBsAg Declined Patients Follow-up Study NCT05977283 | Nanfang Hospital, Southern Medical University | — |
| Completed | A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection NCT05612581 | Vir Biotechnology, Inc. | Phase 1 / Phase 2 |
| Recruiting | Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy i NCT05870969 | Ruijin Hospital | — |
| Recruiting | Real-world Study Optimizing Nucleotide-analogues NCT05937178 | Huashan Hospital | — |
| Active Not Recruiting | Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1) NCT05630807 | GlaxoSmithKline | Phase 3 |
| Active Not Recruiting | Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2) NCT05630820 | GlaxoSmithKline | Phase 3 |
| Unknown | A Study to Evaluate the Efficacy and Safety of ZM-H1505R in Combination With ETV Compared With ETV Monotherapy NCT05484466 | Shanghai Zhimeng Biopharma, Inc. | Phase 2 |
| Active Not Recruiting | Discontinuation of Antiviral Therapy as a Strategy to Cure Hepatitis B NCT05328427 | Göteborg University | N/A |
| Withdrawn | A Study in Chronic Hepatitis B e-Antigen Negative Participants After Discontinuation of Nucleos(t)Ide Analog ( NCT05550519 | Janssen Pharmaceutica N.V., Belgium | EARLY_Phase 1 |
| Terminated | A Single and Multiple Ascending Dose Study of JNJ-64457744 NCT05423106 | Janssen Research & Development, LLC | Phase 1 |
| Completed | An Efficacy and Safety Study of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs (NA), and a Programmed Ce NCT05275023 | Janssen Research & Development, LLC | Phase 2 |
| Unknown | Efficacy and Safety of Avatrombopag for Treating TCP in HBV-ACLF Patients Receiving ALSS Treatment NCT05382013 | Third Affiliated Hospital, Sun Yat-Sen University | Phase 4 |
| Completed | A Study of Cetrelimab in Participants With Chronic Hepatitis B Virus Infection NCT05242445 | Janssen Research & Development, LLC | Phase 1 |
| Unknown | The Effect of Education on Drug Compliance and Quality of Life in Hepatitis B Patients NCT05286216 | Istanbul University - Cerrahpasa | N/A |
| Completed | A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonuc NCT05276297 | GlaxoSmithKline | Phase 2 |
| Completed | Aerobic Exercise Training in Patients With Chronic Hepatitis B and Hepatic Steatosis NCT05265026 | Rigshospitalet, Denmark | N/A |
| Active Not Recruiting | Long-term Safety and Efficacy of Tenofovir Amibufenamide in Patients With CHB NCT06743438 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 4 |
| Unknown | Relationship Between MAFLD and Liver Fibrosis Progression in Patients With Chronic Hepatitis B: a Multicenter NCT05708560 | Erasmus Medical Center | — |
| Unknown | ANRS HB07 IP-Cure-B Proof of Concept (PoC) Clinical Trial. Educating the Liver Immune Environment Through TLR8 NCT05045261 | ANRS, Emerging Infectious Diseases | Phase 2 |
| Unknown | Effect of Entecavir Versus Tenofovir on HBV DNA Level in Peripheral Blood Mononuclear Cells NCT05168293 | Assiut University | — |
| Completed | Study to Evaluate Safety and Efficacy of ASC42 Combined With ETV and PEG-IFN α-2a in Subjects With HBV NCT05107778 | Ascletis Pharmaceuticals Co., Ltd. | Phase 2 |
| Recruiting | Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients NCT05182463 | Third Affiliated Hospital, Sun Yat-Sen University | Phase 4 |
| Unknown | Clinical Characteristics, Natural Outcome and Treatment Optimization of Refractory NCT05376124 | First Affiliated Hospital Xi'an Jiaotong University | — |
| Unknown | An Experimental Study on the Effect of Tenofovir Amibufenamide on Blood Lipid During Anti-HBV Treatment NCT05398393 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | N/A |
| Completed | A Study of JNJ-73763989, JNJ-64300535, and Nucleos(t)Ide Analogs in Virologically Suppressed, Hepatitis B e An NCT05123599 | Janssen Research & Development, LLC | Phase 1 |
| Terminated | A Study of JNJ-73763989, Pegylated Interferon Alpha-2a and Nucleos(t)Ide Analogs in Participants With Chronic NCT05005507 | Janssen Research & Development, LLC | Phase 2 |
| Completed | Evaluation Freethiadine Tolerance in Healthy Subjects and Patients With Chronic Hepatitis B, Pharmacokinetics NCT05391360 | Sunshine Lake Pharma Co., Ltd. | Phase 1 |
| Unknown | A Clinical Research on Disease Progression and Intervention of Chronic HepatitisB NCT05057065 | Hong Ren | — |
| Active Not Recruiting | Safely Discontinue Antiviral Treatment in Patients With Chronic Hepatitis B NCT04782375 | Asan Medical Center | Phase 4 |
| Active Not Recruiting | Effectiveness of Antiviral Treatment in Cirrhotic Patients with Low-level Hepatitis B Virus DNA Levels NCT04780204 | Asan Medical Center | Phase 4 |
| Active Not Recruiting | Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection NCT04856085 | Vir Biotechnology, Inc. | Phase 2 |
| Completed | A Phase II Study of Hepalatide in Subjects With Chronic Hepatitis B NCT04426968 | Shanghai HEP Pharmaceutical Co., Ltd. | Phase 2 |
| Completed | A Multiple-dose Study in Chinese Subjects to Evaluate Safety,Tolerability,PK and PD of ZM-H1505R NCT05470829 | Shanghai Zhimeng Biopharma, Inc. | Phase 1 |
| Unknown | Efficacy and Safety of TAF in Patients With Suboptimal Response to Other Nucleos(t)Ides NCT04201808 | New Discovery LLC | Phase 4 |
| Unknown | Predictive Model for Prognosis of Chronic HBV Infection Mothers NCT04805034 | First Affiliated Hospital Xi'an Jiaotong University | — |
| Completed | Study to Investigate the Safety and Efficacy of BRII-835 and BRII-179 Combination Therapy Treating Chronic Hep NCT04749368 | Brii Biosciences Limited | Phase 2 |
| Unknown | Preventing Mother-to-child Transmission of Hepatitis B Virus With Tenofovir Alafenamide (TAF) NCT05177926 | Nanfang Hospital, Southern Medical University | Phase 4 |
| Completed | Linkage to Care and Treatment of Chronic HBV Patients NCT06658678 | The University of Hong Kong | N/A |
| Terminated | A Study of Safety and Efficacy of ATI-2173 in Combination With Tenofovir Disoproxil Fumarate in Subjects With NCT04847440 | Antios Therapeutics, Inc | Phase 2 |
| Unknown | Molecular Epidemiology of Hepatitis B in Cayenne General Hospital, French Guiana NCT04886102 | Centre Hospitalier de Cayenne | — |
| Completed | A Study of JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virological NCT04667104 | Janssen Research & Development, LLC | Phase 2 |
| Terminated | HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB) NCT04684914 | Altimmune, Inc. | Phase 2 |
| Recruiting | Combination of DPMAS and Low Volume PE for Patients With HBV Related ACLF NCT04597164 | Third Affiliated Hospital, Sun Yat-Sen University | — |
| Unknown | Real World Study About Anti-viral Regimen Adjustment on Achieving Complete Response in CHB Patients NCT04724785 | The Second Affiliated Hospital of Chongqing Medical University | — |
| Unknown | User-friendly HIV Testing and Counseling Services NCT04585165 | Institut de Recherche pour le Developpement | — |
| Terminated | Evaluation HEC121120 Tolerance in Healthy Subjects and Patients With Chronic Hepatitis B, Pharmacokinetics Cha NCT04536532 | Sunshine Lake Pharma Co., Ltd. | Phase 1 / Phase 2 |
| Unknown | Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Type 2 Di NCT05473806 | Seung Up Kim | Phase 4 |
| Completed | A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 NCT04439539 | Janssen Research & Development, LLC | Phase 2 |
| Unknown | A Cross-sectional Study for Renal Function of Patients With Chronic Hepatitis B in China NCT04538651 | Sun Yat-sen University | — |
| Completed | Study of VIR-2218 in Patients With Chronic Hepatitis B in Mainland China NCT04507269 | Brii Biosciences Limited | Phase 2 |
| Withdrawn | Study of IMC-I109V in Non-cirrhotic HBeAg-negative Chronic HBV Infection NCT05867056 | Immunocore Ltd | Phase 1 |
| Completed | A Trial To Evaluate The Efficacy And Safety Of Multiple Combination Therapies In Participants With Chronic Hep NCT04225715 | Hoffmann-La Roche | Phase 2 |
| Completed | A Study of the Oral Farnesoid X Receptor Modulator EYP001a to Assess Its Safety and Anti-viral Effect in Chron NCT04365933 | Enyo Pharma | Phase 2 |
| Terminated | Study of EYP001a to Assess Its Safety and Anti-viral Effect in CHB Patients in Combination With NA (ETV or TD) NCT04465916 | Enyo Pharma | Phase 2 |
| Completed | A Study to Evaluate the Efficacy and Safety of Therapeutic Hepatitis B Vaccine NCT04289987 | CHA Vaccine Institute Co., Ltd. | Phase 2 |
| Recruiting | National Cohort of Patients Co-infected With Hepatitis B and Delta Viruses NCT04166266 | ANRS, Emerging Infectious Diseases | — |
| Completed | A Phase 1 Double-Blinded Study for Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ATI-2173 NCT04248426 | Antios Therapeutics, Inc | Phase 1 |
| Unknown | Maternal Therapy With TAF Versus TDF to Prevent Vertical Transmission of Hepatitis B NCT04211805 | New Discovery LLC | — |
| Withdrawn | A Study to Evaluate a Study Drug, DCB-BO1202, for Alleviating Liver Fibrosis in Liver Cancer Patients NCT02289300 | A2 Healthcare Taiwan Corporation | Phase 2 |
| Unknown | Evaluate the Efficacy and Safety of HLX10 in Chronic Hepatitis B Patients NCT04133259 | Henlix, Inc | Phase 2 |
| Completed | A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negat NCT04129554 | Janssen Sciences Ireland UC | Phase 2 |
| Unknown | Risk of Hepatocellular Carcinoma in Patients Treated With ETV vs TDF for Chronic Hepatitis B With Compensated NCT04160897 | Qing XIe | — |
| Terminated | Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic Treatment Naive Subjects Infected With Hepat NCT04059198 | F-star Therapeutics, Inc. | Phase 2 |
| Completed | A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chro NCT03982186 | Janssen Sciences Ireland UC | Phase 2 |
| Terminated | Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic, Hepatitis B e Antigen-negative Subjects Inf NCT04023721 | F-star Therapeutics, Inc. | Phase 2 |
| Terminated | Evaluating the Effects of Inarigivir on Immune Response and Viral Markers in Chronic Hepatitis B Patients NCT03932513 | F-star Therapeutics, Inc. | Phase 2 |
| Unknown | Chronic HBV Infection in Pregnant Women Taking TAF to Prevent Vertical Transmission NCT04237376 | New Discovery LLC | — |
| Completed | Chronic HBV Management for Asian American NCT04082338 | Temple University | N/A |
| Terminated | Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (G NCT03866187 | GlaxoSmithKline | Phase 1 / Phase 2 |
| Completed | Prediction Model Based on Computed Tomography Liver Volume for the Short-term Mortality in Hepatitis B Related NCT03977857 | First Affiliated Hospital Xi'an Jiaotong University | — |
| Unknown | Tenofovir Alafenamide With Fine Needle Aspiration Biopsy in Chronic Hepatitis B: NCT04070079 | University Health Network, Toronto | Phase 4 |
| Unknown | Ribavirin to Enhance Hepatitis B Virus Nucleotide Analog Antiviral Activity NCT03759782 | Ottawa Hospital Research Institute | Phase 3 |
| Completed | Study of Safety and Tolerability of DCR HBVS NCT03772249 | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | Phase 1 |
| Completed | The Norwegian Nucleoside Analogue Stop Study NCT03681132 | Oslo University Hospital | Phase 4 |
| Active Not Recruiting | The Clinical Cure Project of Chronic Hepatitis B in China NCT04035837 | Third Affiliated Hospital, Sun Yat-Sen University | Phase 4 |
| Completed | Treatment Outcomes in Chronic Hepatitis B Patients on Sequential Therapy With Tenofovir Alafenamide (TAF) NCT03471624 | Stanford University | Phase 4 |
| Completed | A First-In-Human Study to Evaluate Safety, Tolerability, Reactogenicity, and Immunogenicity of JNJ-64300535, a NCT03463369 | Janssen Sciences Ireland UC | Phase 1 |
| Unknown | A Prospective,Observational Follow-up Study of Nucleoside Treated Patients With Chronic Hepatitis B (OCEAN Stu NCT03358108 | Qin Ning | — |
| Completed | Drug Drug Interaction Study for EYP001 With Entecavir NCT03469583 | Enyo Pharma | Phase 1 |
| Completed | Evaluate the Efficacy and Safety to Tenofovir Disoproxil in Chronic Hepatitis B Patients NCT03485534 | Daewoong Pharmaceutical Co. LTD. | Phase 4 |
| Completed | A Study of Switching From Entecavir to Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B NCT03258710 | GlaxoSmithKline | Phase 4 |
| Completed | Evaluation of the Safety and Pharmacology of EYP001 in HBV Subjects NCT03272009 | Enyo Pharma | Phase 1 |
| Withdrawn | A Study Evaluating AL-3778 in Combination With Peginterferon Alpha-2a in Chronic Hepatitis B Subjects NCT03125213 | Alios Biopharma Inc. | Phase 2 |
| Completed | Efficacy and Safety of DA-2802 in Chronic Hepatitis B Patients NCT02967939 | Dong-A ST Co., Ltd. | Phase 3 |
| Completed | Biologic Basis of Liver Cancer From Chronic Hepatitis B NCT03300414 | University of California, Davis | — |
| Completed | EYP001a Food Effect Study in Subjects With Chronic Hepatitis B Virus (HBV) Infection NCT03320616 | Enyo Pharma | Phase 1 |
| Terminated | Clinical and Basic Research of ETV Plus GM-CSF in Chronic Hepatitis B Patients NCT03164889 | Beijing 302 Hospital | N/A |
| Unknown | The Study of Two Different Chinese Traditional Medicine Treatment on Chronic Hepatitis B NCT03018821 | Xi'an Traditional Medicine Hospital | N/A |
| Completed | A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple NCT02952924 | Hoffmann-La Roche | Phase 1 |
| Completed | A Study in Healthy Volunteers and in Participants With Chronic Hepatitis B to Assess Safety, Tolerability, Pha NCT02956850 | Hoffmann-La Roche | Phase 1 |
| Unknown | Cohort Study on People Who Inject Drugs in Senegal NCT03459768 | French National Agency for Research on AIDS and Viral Hepatitis | — |
| Completed | A Long Term Follow-up Study of Patients From the REP 301 Protocol NCT02876419 | Replicor Inc. | — |
| Completed | Study of Hepalatide(L47) at Phase Ib in Healthy Volunteers NCT03023787 | Shanghai HEP Pharmaceutical Co., Ltd. | Phase 1 |
| Terminated | A Study of ALN-HBV in Healthy Adult Volunteers and Non-cirrhotic Patients With Chronic Hepatitis B Virus (HBV) NCT02826018 | Alnylam Pharmaceuticals | Phase 1 |
| Unknown | REALM China Extension Study NCT02974829 | Nanfang Hospital, Southern Medical University | — |
| Completed | Cameroon Baptist Convention Health Board Chronic Hepatitis B Cohort Study NCT02766933 | Mayo Clinic | — |
| Unknown | New Strategy Study of Functional Cure of Chronic Hepatitis B NCT02605252 | Third Affiliated Hospital, Sun Yat-Sen University | N/A |
| Completed | Use of TDF in Patients With Inactive Chronic Hepatitis B Infection NCT02600117 | University Health Network, Toronto | Phase 3 |
| Completed | Study of ARB-001467 in Subjects With Chronic HBV Infection Receiving Nucleos(t)Ide Analogue Therapy NCT02631096 | Arbutus Biopharma Corporation | Phase 2 |
| Terminated | A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7020322 Following NCT02604355 | Hoffmann-La Roche | Phase 1 |
| Unknown | Optimal Time for Tenofovir Treatment of Anti-Hepatitis B Virus (HBV) During the Pregnancy NCT02510963 | First Affiliated Hospital Xi'an Jiaotong University | N/A |
| Unknown | Active Drug Comparative Trial to Evaluate the Antiviral Activity and Safety in Chronic Hepatitis B Patients NCT02588937 | Chong Kun Dang Pharmaceutical | Phase 4 |
| Completed | Safety and Pharmacokinetic Study of Hepalatide(L47) in Healthy Volunteers NCT02612506 | Shanghai HEP Pharmaceutical Co., Ltd. | Phase 1 |
| Unknown | A Hepatitis B With Hepatic Steatosis Study NCT02392598 | Fatty Liver and Alcoholic Liver Disease Study Group, China | — |
| Unknown | Mother-to-child Transmission of HBV in China NCT05172453 | Nanfang Hospital, Southern Medical University | — |
| Unknown | Observational Study on Pregnant Women With Chronic Hepatitis B and Their Infants NCT03539016 | Nanfang Hospital, Southern Medical University | — |
| Completed | A Phase II Clinical Trial of Hydronidone Capsules(F351) in Patients With Liver Fibrosis Induced by HBV Chronic NCT02499562 | Shanghai Genomics, Inc. | Phase 2 |
| Completed | The Safety of Anti-viral Therapy in Preventing HBV MTCT in Pregnant Women After Discontinuation NCT03468907 | Third Affiliated Hospital, Sun Yat-Sen University | Phase 4 |
| Completed | A Study of Treatment With RO6864018 in Virologically Suppressed Participants With Chronic Hepatitis B Virus (H NCT02391805 | Hoffmann-La Roche | Phase 2 |
| Unknown | Compare Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patient NCT02482272 | Asan Medical Center | Phase 4 |
| Unknown | EFFORT Further Extension Study NCT02826070 | Nanfang Hospital, Southern Medical University | Phase 4 |
| Completed | Efficacy and Safety Study of Tenofovir Disoproxil Fumarate (TDF) in Chinese Chronic Hepatitis B (CHB) Subjects NCT02224456 | GlaxoSmithKline | Phase 4 |
| Completed | Tenofovir Disoproxil Fumarate (TDF) 300mg 3 Years RD Therapy Chinese Chronic Hepatitis B (CHN) CHB Multiple Nu NCT02195518 | GlaxoSmithKline | Phase 4 |
| Unknown | Study of Antiretroviral Therapy to Prevent HBV Intrauterine Infection NCT02719808 | First Affiliated Hospital Xi'an Jiaotong University | — |
| Unknown | Emtricitabine for Prevention of Vertical Transmission of HBV in Chinese Pregnant HBsAg Positive Patients NCT02327715 | Asian-Pacific Alliance of Liver Disease, Beijing | Phase 4 |
| Unknown | Emtricitabine Plus Adefovir Dipivoxil for Naive Chinese HBV Related Cirrhosis Patients NCT02327689 | Asian-Pacific Alliance of Liver Disease, Beijing | Phase 4 |
| Unknown | Emtricitabine for Naive Child Chinese Chronic Hepatitis B Patients NCT02327676 | Asian-Pacific Alliance of Liver Disease, Beijing | Phase 4 |
| Unknown | Emtricitabine for Naive Chinese Pregnant Chronic Hepatitis B Patients NCT02327702 | Asian-Pacific Alliance of Liver Disease, Beijing | Phase 4 |
| Completed | An Observational Study in Participants With Chronic Hepatitis B (CHB) Receiving Therapy With Peginterferon Alf NCT02201407 | Hoffmann-La Roche | — |
| Unknown | Emtricitabine for Naive Chinese Chronic Hepatitis B Patients NCT02327663 | Asian-Pacific Alliance of Liver Disease, Beijing | Phase 4 |
| Recruiting | The HOPE Study: Characterizing Patients With Hepatitis B and C NCT02995252 | University of Maryland, Baltimore | — |
| Completed | A Study to Evaluate the Safety and Efficacy of Therapeutic Hepatitis B Vaccine NCT02693652 | CHA Vaccine Institute Co., Ltd. | Phase 1 / Phase 2 |
| Unknown | A Prospective Clinical Trial in Chronic Hepatitis B Patients NAs (Nucleotides or Nucleosides) Experienced (Anc NCT02327416 | Tongji Hospital | Phase 3 |
| Completed | TDF and LdT in Immune-tolerant CHB Patients Awaiting Assisted Reproduction NCT02338674 | Fuzhou General Hospital | Phase 1 / Phase 2 |
| Unknown | Hepatitis B Patients Under Oral Nucleos(t)Ide Treatment With Intermittent Assessment of Kidney Function NCT02267473 | Johann Wolfgang Goethe University Hospital | — |
| Terminated | Effect of RO6871765 and RO7011785 on Immune Response With the Stimulation of Peripheral Blood Mononuclear Cell NCT02498275 | Hoffmann-La Roche | — |
| Completed | Study of Therapeutic Vaccination With Intensified Schedule Plus Pegasys Dual Therapy on Chronic Hepatitis B In NCT02097004 | Seoul National University Hospital | Phase 4 |
| Unknown | Assessment of Hepatitis B Virus Intra-host Population and Host-specific Immune Marker Diversity NCT02148562 | Universitaire Ziekenhuizen KU Leuven | — |
| Completed | Prophylaxis of CHB Patients With Malignant Tumor Receiving Chemotherapy NCT02081469 | Chang Gung Memorial Hospital | Phase 4 |
| Completed | Collection of Samples for the Clinical Evaluation of the Aptima HBV (Hepatitis B Virus) Quant (Quantification) NCT02167113 | Hologic, Inc. | — |
| Terminated | A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After NCT02065336 | Arrowhead Pharmaceuticals | Phase 2 |
| Completed | HBV Envelope Proteins Variability on HBs Antigen Clearance Under Nucleos(t)Ide Analogue Therapy NCT03350074 | Central Hospital, Nancy, France | — |
| Completed | A Study to Collect Blood Biomarker Samples From Participants With Chronic Hepatitis B (CHB) Who Received Treat NCT01855997 | Hoffmann-La Roche | — |
| Completed | Renoprotective Effects of Telbivudine in Chronic Hepatitis B NCT03778567 | The University of Hong Kong | Phase 4 |
| Unknown | Phase Ⅲ Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg-positive Chronic Hepatitis B NCT02366247 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 3 |
| Completed | Combination Therapy With Interferon Plus Interleukin 2 and Hepatitis B Vaccine in Chronic Hepatitis B Patients NCT02360592 | Tongji Hospital | Phase 4 |
| Terminated | Prevalence and Clinical Course of Chronic Hep B Infection in IBD and Rheumatologic Disease NCT02128503 | Chinese University of Hong Kong | N/A |
| Completed | A Study of Pegasys (Peginterferon Alfa-2a) Added to Nucleos(t)Ide Analogue Treatment in Participants With HBeA NCT01706575 | Hoffmann-La Roche | Phase 2 |
| Terminated | A Study of the Safety and Efficacy of Pegylated Inferferon Alfa-2b (PEG-Intron™) Versus Pegylated Interferon A NCT01641926 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | An Observational Study of Pegasys (Peginterferon Alfa-2a) in Chinese Patients With HBeAg Negative Chronic Hepa NCT01730508 | Hoffmann-La Roche | — |
| Completed | A Study Evaluating IL28B Polymorphism in Patients With HBeAg-Negative Chronic Hepatitis B Treated With Pegasys NCT01697501 | Hoffmann-La Roche | Phase 3 |
| Completed | Combination Treatment With REP 2139-Ca and Pegasys in Patients With Chronic Hepatitis B NCT02726789 | Replicor Inc. | Phase 2 |
| Terminated | An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Positive Chronic Hepatitis B NCT01886300 | Hoffmann-La Roche | — |
| Unknown | HBsAg Related Response Guided Therapy NCT01456312 | Gangnam Severance Hospital | Phase 4 |
| Terminated | An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis B Who Have Failed NCT01794234 | Hoffmann-La Roche | — |
| Completed | A Study of Pegasys (Peginterferon Alfa-2a) Versus Untreated Control in Children With HBeAg Positive Chronic He NCT01519960 | Hoffmann-La Roche | Phase 3 |
| Completed | A Retrospective Biomarker Study of Stored Samples Obtained From Patients With Chronic Hepatitis B NCT01705704 | Hoffmann-La Roche | — |
| Completed | Pharmacokinetic (PK) Profiles of Tenofovir Disoproxil Fumarate (TDF) 300 mg in Healthy Chinese Subjects NCT01480622 | GlaxoSmithKline | Phase 1 |
| Completed | Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B With Poor Response to Other Drugs NCT01475851 | GlaxoSmithKline | Phase 3 |
| Completed | Tolerability, Immunogenicity and Efficacy of HB-110 Administered by Electroporation in Chronic Hepatitis B Pat NCT01641536 | Genexine, Inc. | Phase 1 |
| Completed | Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B Untreated With Nucleic Acid Analog NCT01480284 | GlaxoSmithKline | Phase 3 |
| Completed | PROLIFICA - West African Treatment Cohort for Hepatitis B NCT02129829 | Imperial College London | — |
| Unknown | EFFORT Extension Study NCT01529255 | Nanfang Hospital, Southern Medical University | Phase 4 |
| Completed | Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected Patients NCT02646189 | Replicor Inc. | Phase 1 / Phase 2 |
| Completed | An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Positive or HBeAg-Negative Ch NCT01734018 | Hoffmann-La Roche | — |
| Completed | An Observational Study of Peginterferon Alfa-2a (PEGASYS®) in Patients With HBeAg Positive or HBeAg Negative C NCT01667432 | Hoffmann-La Roche | — |
| Completed | Phase II Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg Positive Chronic Hepatitis B NCT02366208 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 2 |
| Terminated | Induction of Fibrosis Regression on Patients With Chronic Hepatitis B Infection NCT01341106 | RWTH Aachen University | Phase 4 |
| Completed | A Follow-Up Study of Patients With HBeAg Positive Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa NCT01645969 | Hoffmann-La Roche | — |
| Completed | Hepatitis B Virus Mutants and the Therapeutic Effect of Peginterferon Alfa-2a in HBeAg-Positive Chronic Hepati NCT01311947 | China Medical University Hospital | — |
| Completed | Lamivudine and Adefovir Dipivoxil Fixed Dose Combination NCT01353742 | GlaxoSmithKline | Phase 1 |
| Completed | Persistence, Adherence and Clinical Effectiveness of Entecavir in Chronic Hepatitis B Patients NCT01356901 | Bristol-Myers Squibb | — |
| Completed | A Two-year Study of Telbivudine in HBeAg Negative Hepatitis NCT01521975 | Third Affiliated Hospital, Sun Yat-Sen University | Phase 4 |
| Withdrawn | A Study of 48 Versus 96 Weeks of Peginterferon Alfa-2a [Pegasys] Treatment, With or Without Entecavir, in Pati NCT01179594 | Hoffmann-La Roche | Phase 4 |
| Unknown | The Development of Diagnostic Biomarker Panels for Hepatitis and Liver Cancer NCT01310062 | Ministry of Health, Malaysia | — |
| Completed | Lamivudine(LAM) Good Responder Study NCT01128686 | ViiV Healthcare | — |
| Unknown | Efficacy Study of Sequential Therapy of Peginterferon Alfa-2a Following Entecavir in Patient With Chronic Hepa NCT01220596 | Hanyang University | Phase 3 |
| Completed | A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Adefovir or Entecavir in Patients With H NCT00922207 | Hoffmann-La Roche | Phase 4 |
| Completed | A Study of Peginterferon Alfa-2a [PEGASYS] in Patients With Chronic Hepatitis B Who Are HBeAg Positive NCT01086085 | Hoffmann-La Roche | Phase 4 |
| Withdrawn | Nabi-HB Administered Subcutaneously in Patients With Hepatitis B Virus Post Liver Transplantation NCT00800787 | Biotest Pharmaceuticals Corporation | Phase 3 |
| Completed | Efficacy and Safety Study of Adefovir and Entecavir for Elderly With Chronic Hepatitis B NCT02075294 | Ying-Jie Ji | — |
| Withdrawn | Entecavir Plus Adefovir in Lamivudine-Resistant Patients NCT00986778 | Bristol-Myers Squibb | Phase 4 |
| Completed | Observe Change of Endotoxaemia and Related Mediators in Patients With Chronic Hepatitis B Virus (HBV) Infectio NCT01107483 | Sun Yat-sen University | — |
| Completed | Entecavir Plus Adefovir in Lamivudine-Resistant Chronic Hepatitis B Patients Who Fail Lamivudine Plus Adefovir NCT01023217 | Asan Medical Center | Phase 4 |
| Completed | A Study to Assess DV-601 in Subjects With Chronic Hepatitis B NCT01023230 | Dynavax Technologies Corporation | Phase 1 |
| Completed | A Study of Pegasys Monotherapy in Patients With Chronic Hepatitis B Who Have Participated in Previous Studies NCT00962975 | Hoffmann-La Roche | Phase 1 |
| Unknown | Patients With Chronic Hepatitis B and Low Viremia Not Receiving Antiviral Therapy NCT01090531 | Johann Wolfgang Goethe University Hospital | — |
| Completed | A Study of Early Immunologic Response in Asian Patients With Chronic Hepatitis B, Treated With Pegasys (Pegint NCT00962871 | Hoffmann-La Roche | Phase 1 |
| Completed | EFFicacy Optimization Research of Telbivudine Therapy NCT00962533 | Nanfang Hospital, Southern Medical University | Phase 4 |
| Completed | Epidemiological Study in Children and Adolescents With Chronic Hepatitis B NCT01163240 | Novartis Pharmaceuticals | — |
| Completed | An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HbeAg-negative Chronic Hepatitis B NCT01283074 | Hoffmann-La Roche | — |
| Completed | Systematic Review of Antiretroviral Treatments for Chronic Hepatitis B (CHB) NCT01155427 | Bristol-Myers Squibb | — |
| Completed | An Observational Cohort Study in Patients With Chronic Hepatitis B Receiving Pegasys NCT01011738 | Hoffmann-La Roche | — |
| Completed | A Study of Combination or Sequential Treatment With PEGASYS (Peginterferon Alfa-2a) and Entecavir in Patients NCT00940485 | Hoffmann-La Roche | Phase 4 |
| Completed | A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon Alfa-2a(4 NCT00927082 | Hoffmann-La Roche | Phase 4 |
| Unknown | A Single-Arm Study Evaluating the Efficacy of Liquid Acupuncture Therapeutics in Chronic Hepatitis B NCT00815464 | Yu Medical Garden | N/A |
| Unknown | Antiviral Therapy in Hepatitis B Virus (HBV)-Related Advanced Liver Disease Patients NCT00823550 | Yonsei University | Phase 4 |
| Completed | Therapeutic Safety and Efficacy of REP 9AC (REP 2055) in HBV or HCV Infected Patients NCT02646163 | Replicor Inc. | Phase 1 / Phase 2 |
| Completed | ADVANCE Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) + Adefovir Dipivoxil in Patients With Hbe(-) NCT00661076 | Hoffmann-La Roche | Phase 3 |
| Completed | Suboptimal Responders to Adefovir Switching to Entecavir NCT00718887 | Bristol-Myers Squibb | Phase 4 |
| Completed | Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivud NCT00410202 | Bristol-Myers Squibb | Phase 3 |
| Completed | Prospective Exploratory Study to Evaluate the Safety and Efficacy of Telbivudine in the Fifth Year of Treatmen NCT00646503 | Novartis | Phase 4 |
| Completed | Prospective Exploratory Study to Describe Hepatitis B Virus (HBV) Kinetics During Treatment With Telbivudine NCT00640588 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Continuing Lamivudine Versus Switching to Entecavir in Patients Who Achieved Undetectable HBV DNA NCT00625339 | Yonsei University | Phase 4 |
| Completed | Continuing Lamivudine Versus Switching to Entecavir in Patients Who Achieved Undetectable Hepatitis B Virus DN NCT00637663 | Pusan National University Hospital | Phase 4 |
| Completed | A Single-arm Study Evaluating the Efficacy and Safety of Telbivudine With or Without add-on Tenofovir in Adult NCT00651209 | Novartis Pharmaceuticals | Phase 4 |
| Completed | Continuing Lamivudine vs Switching to Entecavir in Patients With Detectable HBV DNA NCT00625560 | Yonsei University | Phase 4 |
| Unknown | Early Response to Interferon Combined Short-Term Nucleoside Analogue Therapy in HBeAg(+) Chronic Hepatitis B NCT00860626 | Sun Yat-sen University | N/A |
| Recruiting | "Real-life" Cohort Study on Patients With Chronic HBV Infection in Jiangsu NCT03097952 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | — |
| Terminated | A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Lamivudine Resistant HBeAg-Negative Chronic NCT00460850 | Hoffmann-La Roche | Phase 4 |
| Completed | PegIntron Treatment of Chronic Hepatitis B e Antigen-Positive Patients (P05170/MK-4031-327) NCT00536263 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | To Evaluate Antiviral Efficacy of Telbivudine in Hepatitis B Antigen Positive (HbeAg-positive) Compensated Chr NCT00537537 | Novartis Pharmaceuticals | Phase 4 |
| Completed | A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Entecavir in Treatment-Naive Patients With HBeAg-Positi NCT00614471 | Hoffmann-La Roche | Phase 4 |
| Completed | A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection NCT00423891 | Bristol-Myers Squibb | Phase 1 / Phase 2 |
| Completed | Laboratory Profile of Hepatitis B and C in Users of a Reference Service NCT00512941 | UPECLIN HC FM Botucatu Unesp | — |
| Completed | Lamivudine Therapy in Patients With Prior Entecavir Treatment and Undetectable Viral Load NCT01013272 | The University of Hong Kong | N/A |
| Completed | Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infect NCT00395018 | Bristol-Myers Squibb | Phase 3 |
| Completed | Entecavir Plus Tenofovir Combination Therapy Versus Entecavir Monotherapy in Naive Subjects With Chronic Hepat NCT00410072 | Bristol-Myers Squibb | Phase 3 |
| Completed | A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Hepatitis Be Antigen (HBeAg) Positive Chron NCT00435825 | Hoffmann-La Roche | Phase 4 |
| Completed | A Study of Peginterferon Alfa-2a (40KD) (PEGASYS®) in Participants With Hepatitis B Envelope Antigen (HBeAg) - NCT00436163 | Hoffmann-La Roche | Phase 4 |
| Unknown | Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Negative Chronic Hepatitis B NCT00917761 | National Taiwan University Hospital | Phase 4 |
| Unknown | Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Positive Chronic Hepatitis B NCT00921180 | National Taiwan University Hospital | Phase 4 |
| Unknown | Influence of Antiviral Treatment to the Long-Term Prognosis of Patients With Chronic HBV Infection NCT00810524 | Sun Yat-sen University | Phase 4 |
| Completed | Hepatic Safety of Currently Used Antiretroviral Regimens in Patients With Chronic Hepatitis Under Real Life Co NCT01908660 | Valme University Hospital | — |
| Completed | A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis B. NCT00487747 | Hoffmann-La Roche | Phase 4 |
| Completed | SOFIA-LTT Study: A Study of Intermittent Long Term Treatment With PEGASYS (Peginterferon Alfa-2a (40KD)) in Pa NCT00442572 | Hoffmann-La Roche | Phase 2 |
| Completed | Study of Adefovir Dipivoxil for Korean Patients With Chronic Hepatitis B(CHB) Who Have Completed ADF 103814 NCT00403585 | GlaxoSmithKline | Phase 4 |
| Completed | Special Drug Use Investigation for ZEFIX (Lamivudine) Tablet (HBV Cirrhosis) NCT01376154 | GlaxoSmithKline | — |
| Completed | A Study of Peginterferon Alfa-2a in Participants With Chronic Hepatitis B Virus (HBV) in an Expanded Access Pr NCT02791269 | Hoffmann-La Roche | Phase 4 |
| Completed | An Expanded Access Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Negative Chronic Hepatitis NCT01787279 | Hoffmann-La Roche | Phase 4 |
| Completed | Efficacy of Peginterferon Alfa-2b in Previously Untreated Subjects With Chronic Hepatitis B and D Co-infection NCT00686790 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B. NCT01519921 | Hoffmann-La Roche | Phase 4 |
| Completed | A Study to Evaluate Efficacy and Safety of Peginterferon Alfa-2a (Pegasys) and Adeforvir Dipivoxil (ADV) in Pa NCT02598063 | Hoffmann-La Roche | Phase 4 |
| Completed | Long-Term Lamivudine Therapy for Chronic Hepatitis B NCT00120354 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 4 |
| Completed | Analysis of HBV-Specific Immune Response in Patients With HBeAg Negative Chronic Hepatitis B Treated With Pega NCT01237496 | Hoffmann-La Roche | Phase 3 |
| Terminated | Open-label Treatment Extension Study for Patients Who Complete Study RNA200103-201 NCT00230490 | Bausch Health Americas, Inc. | Phase 2 |
| Completed | Adefovir Dipivoxil For The Treatment Of Patients With Chronic Hepatitis B Related Advanced Fibrosis Or Cirrhos NCT00347009 | GlaxoSmithKline | Phase 4 |
| Completed | A Study of Pegylated Interferon Alfa-2a and Lamivudine in Patients With HBeAg-Negative Chronic Hepatitis B Vir NCT01095835 | Hoffmann-La Roche | Phase 3 |
| Completed | An Open Label, Multi Centre Phase IV Study of Adefovir Dipivoxil in Korean Patients With Chronic Hepatitis B ( NCT01205165 | GlaxoSmithKline | Phase 4 |
| Completed | Efficacy and Safety of Intramuscular HBIG Grifols for the Prevention of Recurrence After Liver Transplantation NCT00895713 | Instituto Grifols, S.A. | Phase 2 |
| Completed | A Study of PEGASYS (Peginterferon Alfa-2a [40KD]) in Patients With Hepatitis B e Antigen (HBeAg)-Negative Chro NCT02570191 | Hoffmann-La Roche | Phase 4 |
| Unknown | Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C/Hepatitis B Co-Infection and Chronic Hepatitis C NCT00154869 | National Taiwan University Hospital | Phase 3 |
| Completed | Dose-Ranging Study of Pradefovir in Patients With Compensated Hepatitis B NCT00230503 | Bausch Health Americas, Inc. | Phase 2 |
| Completed | Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis NCT00076336 | Novartis Pharmaceuticals | Phase 3 |
| Completed | A Study of Peginterferon Alfa-2a (Pegasys) in Participants With Hepatitis B E-Antigen (HBeAg)-Positive Chronic NCT02604823 | Hoffmann-La Roche | Phase 4 |
| Completed | Evaluation of Serum Levels and Pharmacokinetics of a New Hepatitis B Immune Globulin Following Liver Transplan NCT00838071 | Instituto Grifols, S.A. | Phase 3 |
| Completed | KRN7000 in Chronic Hepatitis B NCT00363155 | Foundation for Liver Research | Phase 1 / Phase 2 |
| Completed | Safety and Antiviral Activity Study of ACH-126,443 (Beta-L-Fd4C) in Treatment-naive Adults With Chronic Hepati NCT00034359 | Alexion Pharmaceuticals, Inc. | Phase 2 |
| Withdrawn | Comparison of Telbivudine Versus Lamivudine on the Early Dynamics and Kinetics of Viral Suppression in Chronic NCT00710216 | University of Ulm | Phase 4 |
| Completed | Safety and Acceptability of a Vaginal Microbicide NCT00111943 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |